Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.09
HSIC's Cash to Debt is ranked lower than
56% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.62 vs. HSIC: 0.09 )
HSIC' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.09

Equity to Asset 0.46
HSIC's Equity to Asset is ranked higher than
74% of the 61 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.42 vs. HSIC: 0.46 )
HSIC' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.67
Current: 0.46

0.21
0.67
Interest Coverage 24.59
HSIC's Interest Coverage is ranked higher than
70% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.02 vs. HSIC: 24.59 )
HSIC' s 10-Year Interest Coverage Range
Min: 4.68   Max: 24.59
Current: 24.59

4.68
24.59
F-Score: 7
Z-Score: 4.97
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 6.86
HSIC's Operating margin (%) is ranked higher than
77% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.73 vs. HSIC: 6.86 )
HSIC' s 10-Year Operating margin (%) Range
Min: -1.95   Max: 7.27
Current: 6.86

-1.95
7.27
Net-margin (%) 4.49
HSIC's Net-margin (%) is ranked higher than
74% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.25 vs. HSIC: 4.49 )
HSIC' s 10-Year Net-margin (%) Range
Min: -2.24   Max: 4.76
Current: 4.49

-2.24
4.76
ROE (%) 16.36
HSIC's ROE (%) is ranked higher than
88% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.14 vs. HSIC: 16.36 )
HSIC' s 10-Year ROE (%) Range
Min: -0.55   Max: 15.99
Current: 16.36

-0.55
15.99
ROA (%) 7.91
HSIC's ROA (%) is ranked higher than
90% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.17 vs. HSIC: 7.91 )
HSIC' s 10-Year ROA (%) Range
Min: -0.31   Max: 8.37
Current: 7.91

-0.31
8.37
ROC (Joel Greenblatt) (%) 44.46
HSIC's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 25.75 vs. HSIC: 44.46 )
HSIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 17.57   Max: 49.88
Current: 44.46

17.57
49.88
Revenue Growth (3Y)(%) 10.60
HSIC's Revenue Growth (3Y)(%) is ranked higher than
73% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.50 vs. HSIC: 10.60 )
HSIC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.5   Max: 135.2
Current: 10.6

4.5
135.2
EBITDA Growth (3Y)(%) 11.10
HSIC's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.20 vs. HSIC: 11.10 )
HSIC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 8.3   Max: 89.5
Current: 11.1

8.3
89.5
EPS Growth (3Y)(%) 12.20
HSIC's EPS Growth (3Y)(%) is ranked higher than
62% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 17.30 vs. HSIC: 12.20 )
HSIC' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 69.3
Current: 12.2

0
69.3
» HSIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

HSIC Guru Trades in Q4 2013

Jim Simons 13,500 sh (New)
Joel Greenblatt 5,498 sh (New)
Steven Cohen 17,723 sh (+181.99%)
Columbia Wanger 1,225,500 sh (unchged)
Chuck Royce 7,430 sh (unchged)
Robert Olstein Sold Out
Jeremy Grantham 57,200 sh (-0.17%)
Ron Baron 455,496 sh (-0.88%)
Mario Gabelli 226,701 sh (-1.09%)
Ken Fisher 542,293 sh (-7.47%)
Paul Tudor Jones 5,654 sh (-24.61%)
» More
Q1 2014

HSIC Guru Trades in Q1 2014

Joel Greenblatt 84,157 sh (+1430.68%)
Jeremy Grantham 158,951 sh (+177.89%)
Ken Fisher 544,914 sh (+0.48%)
Ron Baron 455,571 sh (+0.02%)
Jim Simons Sold Out
Mario Gabelli 218,901 sh (-3.44%)
Chuck Royce 6,630 sh (-10.77%)
Columbia Wanger 1,007,500 sh (-17.79%)
Paul Tudor Jones 4,300 sh (-23.95%)
Steven Cohen 1,681 sh (-90.52%)
» More
Q2 2014

HSIC Guru Trades in Q2 2014

Jeremy Grantham 233,078 sh (+46.64%)
Paul Tudor Jones 6,000 sh (+39.53%)
Columbia Wanger 1,007,500 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce Sold Out
Ron Baron 454,034 sh (-0.34%)
Ken Fisher 543,004 sh (-0.35%)
Mario Gabelli 213,701 sh (-2.38%)
» More
Q3 2014

HSIC Guru Trades in Q3 2014

Ray Dalio 2,250 sh (New)
Jim Simons 52,206 sh (New)
Paul Tudor Jones 6,900 sh (+15%)
Ken Fisher 534,025 sh (-1.65%)
Mario Gabelli 207,141 sh (-3.07%)
Jeremy Grantham 221,978 sh (-4.76%)
Ron Baron 409,429 sh (-9.82%)
Columbia Wanger 883,500 sh (-12.31%)
» More
» Details

Insider Trades

Latest Guru Trades with HSIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ray Dalio 2014-09-30 New Buy$114.85 - $120.07 $ 137.5116%2250
Joel Greenblatt 2014-06-30 Sold Out 0.15%$112.43 - $120.48 $ 137.5118%0
Joel Greenblatt 2014-03-31 Add 1430.68%0.14%$110.21 - $120.17 $ 137.5118%84157
Robert Olstein 2013-12-31 Sold Out 0.46%$102.98 - $115.22 $ 137.5123%0
Joel Greenblatt 2013-12-31 New Buy0.02%$102.98 - $115.22 $ 137.5123%5498
Robert Olstein 2013-09-30 Reduce -36.96%0.26%$96.81 - $107.16 $ 137.5133%29000
John Keeley 2013-09-30 Sold Out 0.01%$96.81 - $107.16 $ 137.5133%0
Tweedy Browne 2013-03-31 Sold Out 0.56%$80.42 - $92.55 $ 137.5157%0
Joel Greenblatt 2013-03-31 Sold Out 0.02%$80.42 - $92.55 $ 137.5157%0
John Keeley 2013-03-31 Reduce -26.54%0.01%$80.42 - $92.55 $ 137.5157%16830
John Keeley 2012-12-31 Reduce -56.29%0.05%$73.75 - $82.23 $ 137.5175%22910
Joel Greenblatt 2012-09-30 New Buy0.02%$74.64 - $80.27 $ 137.5177%4014
Robert Olstein 2012-06-30 Reduce -26.47%0.24%$72.53 - $79.56 $ 137.5182%50000
Ken Fisher 2012-06-30 Reduce -23.69%0.03%$72.53 - $79.56 $ 137.5182%475119
Robert Olstein 2011-12-31 Add 18.33%0.14%$59.52 - $70.98 $ 137.51115%71000
Ron Baron 2011-09-30 Reduce -36.26%0.1%$59.76 - $74.91 $ 137.51107%454271
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Henry Schein Inc

Weekly 52-Week Highs Highlight: IHG, HSIC, GGP, AAL
According to GuruFocus list of 52-week highs, InterContinental Hotels Group PLC, Henry Schein Inc., General Growth Properties Inc. and American Airlines Group Inc. have all reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.90
HSIC's P/E(ttm) is ranked higher than
73% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 26.20 vs. HSIC: 25.90 )
HSIC' s 10-Year P/E(ttm) Range
Min: 12.03   Max: 35.43
Current: 25.9

12.03
35.43
P/B 4.12
HSIC's P/B is ranked higher than
65% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.03 vs. HSIC: 4.12 )
HSIC' s 10-Year P/B Range
Min: 1.57   Max: 4.12
Current: 4.12

1.57
4.12
P/S 1.16
HSIC's P/S is ranked higher than
68% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.95 vs. HSIC: 1.16 )
HSIC' s 10-Year P/S Range
Min: 0.48   Max: 1.16
Current: 1.16

0.48
1.16
PFCF 23.15
HSIC's PFCF is ranked higher than
82% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 49.94 vs. HSIC: 23.15 )
HSIC' s 10-Year PFCF Range
Min: 9.15   Max: 35.64
Current: 23.15

9.15
35.64
EV-to-EBIT 17.64
HSIC's EV-to-EBIT is ranked higher than
75% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.48 vs. HSIC: 17.64 )
HSIC' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 20.5
Current: 17.64

7.3
20.5
PEG 2.33
HSIC's PEG is ranked higher than
77% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.85 vs. HSIC: 2.33 )
HSIC' s 10-Year PEG Range
Min: 0.53   Max: 3.4
Current: 2.33

0.53
3.4
Shiller P/E 32.21
HSIC's Shiller P/E is ranked higher than
79% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 42.91 vs. HSIC: 32.21 )
HSIC' s 10-Year Shiller P/E Range
Min: 16.95   Max: 40.01
Current: 32.21

16.95
40.01
Current Ratio 1.72
HSIC's Current Ratio is ranked higher than
74% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.54 vs. HSIC: 1.72 )
HSIC' s 10-Year Current Ratio Range
Min: 1.72   Max: 2.98
Current: 1.72

1.72
2.98
Quick Ratio 0.96
HSIC's Quick Ratio is ranked higher than
56% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.13 vs. HSIC: 0.96 )
HSIC' s 10-Year Quick Ratio Range
Min: 0.96   Max: 2.1
Current: 0.96

0.96
2.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 41.80
HSIC's Price/Tangible Book is ranked higher than
61% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.89 vs. HSIC: 41.80 )
HSIC' s 10-Year Price/Tangible Book Range
Min: 2.37   Max: 35.63
Current: 41.8

2.37
35.63
Price/DCF (Projected) 1.40
HSIC's Price/DCF (Projected) is ranked higher than
80% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.50 vs. HSIC: 1.40 )
HSIC' s 10-Year Price/DCF (Projected) Range
Min: 0.76   Max: 22.69
Current: 1.4

0.76
22.69
Price/Median PS Value 1.38
HSIC's Price/Median PS Value is ranked higher than
66% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.33 vs. HSIC: 1.38 )
HSIC' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 1.51
Current: 1.38

0.29
1.51
Price/Peter Lynch Fair Value 2.39
HSIC's Price/Peter Lynch Fair Value is ranked higher than
83% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 9999.00 vs. HSIC: 2.39 )
HSIC' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.59   Max: 3.33
Current: 2.39

0.59
3.33
Price/Graham Number 6.59
HSIC's Price/Graham Number is ranked higher than
68% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.62 vs. HSIC: 6.59 )
HSIC' s 10-Year Price/Graham Number Range
Min: 1.1   Max: 43.52
Current: 6.59

1.1
43.52
Earnings Yield (Greenblatt) 5.70
HSIC's Earnings Yield (Greenblatt) is ranked higher than
73% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.70 vs. HSIC: 5.70 )
HSIC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.9   Max: 13.6
Current: 5.7

4.9
13.6
Forward Rate of Return (Yacktman) 14.50
HSIC's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.44 vs. HSIC: 14.50 )
HSIC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 10.5   Max: 29.2
Current: 14.5

10.5
29.2

Business Description

Industry: Medical Distribution » Medical Distribution
Compare:ABC, MCK, CAH, SHTDF, PDCO » details
Traded in other countries:HS2.Germany,
Henry Schein, Inc., was incorporated in Delaware. The Company is engaged in offering a selection of products and services and value-added solutions for operating efficient practices and delivering high quality care. The Company operates through a centralized and automated distribution network with a selection of more than 96,000 branded products and Henry Schein private brand products in stock, as well as more than 110,000 additional products available as special order items. It also offers its customers technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services. The Company conducts its business through two reportable segments: health care distribution and technology and value-added services. The health care distribution reportable segment aggregates its global dental, animal health and medical operating segments. This segment consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Company's global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. The Company's value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The Company's main competitors include the GACD Group, Pluradent AG & Co., Lifco AB, Planmeca Oy, Billericay Dental Supply Co. Ltd., National Veterinary Services and Alcyon SA. The Company's business is subject to local, state, federal and foreign governmental laws and regulations applicable to the distribution of pharmaceuticals and medical devices. The Company's businesses are subject to various additional federal, state, local and foreign laws and regulations, including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially hazardous substances, and safe working conditions. Its businesses are also subject to requirements of similar and other foreign governmental laws and regulations affecting its operations abroad.
» More Articles for HSIC

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: DLTR, NTES, HSIC, ADM Nov 23 2014 
AmerisourceBergen Is a Center Piece in the Pharma Industry Sep 30 2014 
Weekly 52-Week Highs Highlight: IHG, HSIC, GGP, AAL Jun 02 2014 
Mario Gabelli on Aging America, Alcohol, Twitter, Facebook Dec 17 2013 
Importance of Leadership in a 5-Star Company Feb 05 2013 
Comment for Buffett-Munger Screener - Good Companies at Fair or Undervalued Prices -- GuruFocus.com Oct 12 2012 
Looking at the Big Picture Apr 25 2012 
Henry Schein Inc. (HSIC) President, COO James P Breslawski sells 46,000 Shares Mar 07 2011 
Henry Schein Inc. (HSIC) EVP, CFO Steven Paladino sells 26,000 Shares Feb 25 2011 
Henry Schein Inc. (HSIC) Chairman, CEO Stanley M Bergman sells 100,000 Shares May 14 2010 

More From Other Websites
[video]'Mad Money' Lightning Round: You Have a Winner With Lithia Motors Dec 20 2014
Shares Fall as athenahealth's 2015 Outlook Fails to Impress Dec 11 2014
Henry Schein Vice President Dr. Robert Gottlander Becomes Lifetime Honorary Member of the American... Dec 11 2014
Henry Schein's Chairman and CEO Honored at MedShare's Fourth Annual "Share the Good Gala" Dec 09 2014
The Global Dental Device Market to hit $12.7 Billion by 2020 Propelled by a Surge in Oral Diseases... Dec 09 2014
Henry Schein's 16th Annual Holiday Cheer for Children Brightens The Holidays For More Than 1,000... Dec 08 2014
Henry Schein's 16th Annual Holiday Cheer for Children Brightens The Holidays For More Than 1,000... Dec 08 2014
Henry Schein Announces $300 Million Increase To Share Repurchase Plan Dec 05 2014
Henry Schein Announces $300 Million Increase To Share Repurchase Plan Dec 05 2014
Henry Schein Appoints Dr. Lawrence S. Bacow to Its Board of Directors Dec 03 2014
HENRY SCHEIN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Dec 03 2014
Henry Schein Appoints Dr. Lawrence S. Bacow to Its Board of Directors Dec 03 2014
Henry Schein, Cardinal Health Sign Physician Service Deal Nov 25 2014
Henry Schein To Present At Two Investor Conferences In December Nov 21 2014
Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices Nov 21 2014
Cardinal Health and Henry Schein Enter into Long-term Strategic Agreement to Serve Physician Offices Nov 21 2014
Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices Nov 21 2014
Henry Schein Strong on Healthy Track Record, Fundamentals Nov 20 2014
Henry Schein To Present At Two Investor Conferences In December Nov 18 2014
HENRY SCHEIN INC Financials Nov 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK